{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:01:10Z","timestamp":1790204470714,"version":"4.1.0"},"reference-count":22,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endoscopy"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Endoscopic sleeve gastroplasty (ESG) and semaglutide are established therapies for obesity. However, comparative real-world data remain limited. We compared the effectiveness and safety of ESG versus oral semaglutide 14 mg in adults with obesity.<\/jats:p>\n                  <jats:p>In a real-world retrospective comparative cohort study between January 2024 and April 2025, adults aged 18\u201365 years with body mass index (BMI) \u226530, or \u226527 kg\/m2 with obesity-related comorbidity, treated with either ESG or oral semaglutide 14mg daily, and having 6-months\u2019 follow-up were included. Primary endpoint was percentage total body weight loss (%TBWL) at 6 months. Secondary outcomes included treatment responder rates, adverse events, and 12-month weight outcomes. Analyses included Welch\u2019s two-sample t-tests, analysis of covariance adjusted for age, sex, baseline BMI, and diabetes, inverse probability of treatment weighting (IPTW), and 1:1 propensity score matching.<\/jats:p>\n                  <jats:p>150 patients were included (ESG n=50; semaglutide n=100). Baseline characteristics were broadly similar between groups. At 6 months, mean %TBWL was significantly higher with ESG than semaglutide (12.72\u00b15.67% vs 8.67\u00b13.84%, P=0.0001) that remained after covariate adjustment (adjusted mean difference 4.04%, P=0.0001), IPTW analysis (P&lt;0.001), and propensity-matched analysis (P=0.021). Responder rates \u226510%TBWL were achieved in 70% with ESG versus 43% with semaglutide (relative risk [RR] 0.62, 95%CI 0.46\u20130.82, P=0.0009), and \u226515%TBWL in 36% versus 7% (RR 0.20, 95%CI 0.09\u20130.44, P=0.0006). There were no major adverse events. At 12 months, mean %TBWL was 11.92\u00b16.93 with ESG and 10.91\u00b14.66 with semaglutide (P=0.41). During follow-up, 18 patients discontinued semaglutide and 5 ESG patients initiated semaglutide.<\/jats:p>\n                  <jats:p>ESG was associated with greater short-term weight loss and higher responder rates than oral semaglutide 14mg. At 12 months, weight loss was sustained in both groups without significant between-group difference. These preliminary findings should be interpreted with caution in absence of randomized trial design.<\/jats:p>","DOI":"10.1055\/a-2891-4165","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T23:11:01Z","timestamp":1780960261000},"page":"1084-1090","source":"Crossref","is-referenced-by-count":1,"title":["Endoscopic sleeve gastroplasty versus oral semaglutide for obesity: a real-world comparative cohort study"],"prefix":"10.1055","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3469-0164","authenticated-orcid":false,"given":"Nitin","family":"Jagtap","sequence":"additional","affiliation":[{"name":"Asian Institute of Gastroenterology, India","place":["Hyderabad"],"department":["Department of Medical Gastroenterology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Golchha","sequence":"additional","affiliation":[{"name":"Asian Institute of Gastroenterology, India","place":["Hyderabad"],"department":["Department of Medical Gastroenterology"]},{"name":"Asian Institute of Gastroenterology, India","place":["Hyderabad"],"department":["Department of Medical Gastroenterology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4347-8314","authenticated-orcid":false,"given":"Anudeep","family":"Katrevula","sequence":"additional","affiliation":[{"name":"Asian Institute of Gastroenterology, India","place":["Hyderabad"],"department":["Department of Medical Gastroenterology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4405-779X","authenticated-orcid":false,"given":"Shujaath","family":"Asif","sequence":"additional","affiliation":[{"name":"Asian Institute of Gastroenterology, India","place":["Hyderabad"],"department":["Department of Medical Gastroenterology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7579-9986","authenticated-orcid":false,"given":"Hardik","family":"Rughwani","sequence":"additional","affiliation":[{"name":"Asian Institute of Gastroenterology, India","place":["Hyderabad"],"department":["Department of Medical Gastroenterology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0945-8563","authenticated-orcid":false,"given":"Krithi Krishna","family":"Koduri","sequence":"additional","affiliation":[{"name":"Asian Institute of Gastroenterology, India","place":["Hyderabad"],"department":["Department of Medical Gastroenterology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Balenki","sequence":"additional","affiliation":[{"name":"Asian Institute of Gastroenterology, India","place":["Hyderabad"],"department":["Department of Medical Gastroenterology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Kalapala","sequence":"additional","affiliation":[{"name":"Asian Institute of Gastroenterology, India","place":["Hyderabad"],"department":["Department of Medical Gastroenterology"]},{"name":"Asian Institute of Gastroenterology, India","place":["Hyderabad"],"department":["Department of Medical Gastroenterology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Nageshwar","family":"Reddy","sequence":"additional","affiliation":[{"name":"Asian Institute of Gastroenterology, India","place":["Hyderabad"],"department":["Department of Medical Gastroenterology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.2337\/dc06-2544","article-title":"Effect of BMI on lifetime risk for diabetes in the U.S","volume":"30","author":"KM Narayan","year":"2007","journal-title":"Diabetes Care"},{"key":"ref2","first-page":"397","article-title":"Beneficial health effects of modest weight loss","volume":"16","author":"DJ Goldstein","year":"1992","journal-title":"Int J Obes Relat Metab Disord"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0140-6736(22)01280-6","article-title":"Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial","volume":"400","author":"BK Abu Dayyeh","year":"2022","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1007\/s12664-021-01202-7","article-title":"Endoscopic sleeve gastroplasty \u2013 minimally invasive treatment for non-alcoholic fatty liver disease and obesity","volume":"40","author":"N Jagtap","year":"2021","journal-title":"Indian J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.10.027","article-title":"Endoscopic sleeve gastroplasty plus lifestyle intervention in patients with metabolic dysfunction-associated steatohepatitis: a multicenter, sham-controlled, randomized trial","volume":"23","author":"J Abad","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1055\/s-0045-1811546","article-title":"Efficacy and safety of endoscopic gastroplasty versus lifestyle modification for obesity: a meta-analysis of randomized controlled trials with technique-specific subgroup analysis","author":"N Jagtap","year":"2025","journal-title":"J Dig Endosc"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"JPH Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1056\/NEJMoa2500969","article-title":"Oral semaglutide at a dose of 25 mg in adults with overweight or obesity","volume":"393","author":"S Wharton","year":"2025","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"FK Knop","year":"2023","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-025-01856-7","article-title":"Oral semaglutide for weight loss and liver fibrosis in overweight and obesity: a randomized controlled trial","author":"A Katrevula","year":"2025","journal-title":"Indian J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-025-09218-1","article-title":"Prospective, matched case-control study of endoscopic sleeve gastroplasty and semaglutide in patients with metabolic dysfunction-associated steatotic liver disease at one year","author":"S Kumar","year":"2025","journal-title":"Dig Dis Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jviscsurg.2024.12.003","article-title":"Position statement and guidelines about endoscopic sleeve gastroplasty (ESG) also known as \"Endo-sleeve\"","volume":"162","author":"C Baratte","year":"2025","journal-title":"J Visc Surg"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.gie.2019.06.013","article-title":"Endoscopic sleeve gastroplasty in the management of overweight and obesity: an international multicenter study","volume":"90","author":"S Barrichello","year":"2019","journal-title":"Gastrointest Endosc"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.cgh.2020.09.055","article-title":"Five-year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity","volume":"19","author":"RZ Sharaiha","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"VR Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial","volume":"42","author":"HW Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"R Pratley","year":"2019","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/cob.70001","article-title":"Revisional endoscopic sleeve gastroplasty versus semaglutide and tirzepatide for weight recidivism after sleeve gastrectomy","volume":"15","author":"F Bahdi","year":"2025","journal-title":"Clin Obes"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4062\/biomolther.2024.228","article-title":"An overview of existing and emerging weight-loss drugs to target obesity-related complications: insights from clinical trials","volume":"33","author":"MK Kim","year":"2025","journal-title":"Biomol Ther (Seoul)"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/den.14994","article-title":"Endoscopic sleeve gastroplasty \u2013 Current status and future perspectives","volume":"37","author":"SK Ng","year":"2025","journal-title":"Dig Endosc"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1007\/s11695-024-07510-z","article-title":"IFSO Bariatric Endoscopy Committee evidence-based review and position statement on endoscopic sleeve gastroplasty for obesity management","volume":"34","author":"BKA Dayyeh","year":"2024","journal-title":"Obes Surg"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/dom.14863","article-title":"Semaglutide for the treatment of overweight and obesity: a review","volume":"25","author":"NC Bergmann","year":"2023","journal-title":"Diabetes Obes Metab"}],"container-title":["Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2891-4165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:38:34Z","timestamp":1790203114000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2891-4165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":22,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2891-4165","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0013-726X","1438-8812"],"issn-type":[{"value":"0013-726X","type":"print"},{"value":"1438-8812","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,8]]},"published":{"date-parts":[[2026,6,8]]}}}